MODEL OF SCHIZOPHRENIA GATING DEFICITS: NMDA EFFECTS
精神分裂症门控缺陷模型:NMDA 效应
基本信息
- 批准号:3429389
- 负责人:
- 金额:$ 7.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-03-01 至 1993-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This proposal seeks to investigate the involvement of the
N-methyl-D-aspartate (NMDA) receptor complex in the pathophysiology of
schizophrenia. Recent pharmacological, physiological and behavioral studies
have indicated that the psychoactive effects of phencyclidine (PCP) are
mediated by a component of the NMDA complex. PCP, a drug of abuse, has been
noted in several studies to produce a toxic psychosis which in many ways
resembles schizophrenia. Our proposed studies will employ the prepulse
inhibition (PPI) model of sensorimotor gating in rats to investigate how
NMDA receptor perturbation might relate to information processing deficits
often noted in schizophrenia. We have found in preliminary studies that PCP
produces deficits in PPI similar to those seen in schizophrenic patients
and in animals treated with dopamine agonists. Specifically, we intend to
isolate the receptor component responsible for PPI deficits through the
testing of specific ligands at the three major known components of the NMDA
receptor complex: the NMDA site, the PCP site, and the glycine site.
Available evidence indicates that activity at NMDA and glycine sites can
profoundly influence the effects of PCP, and so manipulation of these sites
may reveal the overall mechanism by which this complex regulates sensory
gating functions. Rats will be tested in a previously-developed procedure
where loud acoustic stimuli are presented either alone or preceded by
weaker stimuli. Whole-body startle responses in each condition are recorded
and compared. Presentation of the weaker stimulus, or prepulse, typically
reduces, or gates, the effects of the main startling event. Antagonists of
the NMDA site and glycine site, which in some ways mimic the effects of
PCP, will be administered and the resulting effects compared with those of
PCP and PCP-like drugs. We will also explore the influence of the sigma
opioid receptor in the production of gating deficits. Some sigma opiates
have been reported to produce psychosis-like effects in humans, and recent
evidence has indicated that many sigma behavioral actions may indeed be
mediated at the PCP receptor. We will test psychotomimetic opioids and
other drugs which bind to the high- and low-affinity sigma sites in an
effort to elucidate the importance of this system in the production of
gating deficits by PCP. We hope that these studies will provide a better
overall understanding of sensory gating disturbances in schizophrenia and
the influences of NMDA function in the genesis of this devastating disease.
Such information could lead to the development of new pharmacotherapeutic
approaches for schizophreniform psychoses.
这项提案旨在调查
N-甲基-D-天冬氨酸(NMDA)受体复合体在心肌梗死病理生理中的作用
精神分裂症。最近的药理学、生理学和行为学研究
已经表明苯环利定(PCP)的精神活性作用是
由NMDA复合体的一种成分介导。五氯苯酚,一种滥用的药物,一直被
在几项研究中指出会产生一种中毒性精神病,在许多方面
像是精神分裂症。我们提议的研究将采用预脉冲
大鼠感觉运动门抑制(PPI)模型的建立
NMDA受体紊乱可能与信息加工缺陷有关
常见于精神分裂症。我们在初步研究中发现,五氯酚
产生与精神分裂症患者类似的PPI缺陷
在用多巴胺激动剂治疗的动物中也是如此。具体来说,我们打算
通过以下途径分离导致PPI缺陷的受体组件
对NMDA三个主要已知成分的特定配体的测试
受体复合体:NMDA位点、PCP位点和甘氨酸位点。
现有证据表明,NMDA和甘氨酸位点的活动可以
深刻地影响了PCP的效果,因此对这些站点的操纵
可能揭示这种复合体调节感官的整体机制
选通功能。老鼠将在之前开发的程序中进行测试
其中大声的声刺激单独呈现或在其之前呈现
较弱的刺激。记录每种情况下的全身惊吓反应
并进行了比较。呈现较弱的刺激,或预脉冲,通常
减少或关闭主要令人震惊的事件的影响。拮抗剂
NMDA位点和甘氨酸位点,在某些方面模拟了
将实施PCP,并将产生的效果与
五氯苯酚和五氯苯酚类药物。我们还将探讨西格玛的影响
阿片受体在门控缺陷的产生。一些西格玛阿片类药物
据报道在人类身上会产生类似精神病的影响,最近
有证据表明,许多西格玛行为可能确实是
通过PCP受体进行调节。我们将测试精神类阿片类药物和
其他结合高亲和力和低亲和力的Sigma位点的药物
努力阐明这一制度在生产中的重要性
五氯联苯控制赤字。我们希望这些研究将提供更好的
对精神分裂症患者感觉门控障碍的总体认识
NMDA功能在这种毁灭性疾病的发生中的影响。
这些信息可能会导致新药物疗法的发展
精神分裂样精神病的治疗方法。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT S. MANSBACH其他文献
ROBERT S. MANSBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT S. MANSBACH', 18)}}的其他基金
MODEL OF SCHIZOPHRENIA GATING DEFICITS: NMDA EFFECTS
精神分裂症门控缺陷模型:NMDA 效应
- 批准号:
3429388 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别:
相似海外基金
DA/PCP RECEPTOR INHERITANCE: CLASSICAL GENETIC ANALYSIS
DA/PCP 受体遗传:经典遗传分析
- 批准号:
2117880 - 财政年份:1994
- 资助金额:
$ 7.15万 - 项目类别:
U.S-France Joint Seminar: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neural Modulation and Protection, Montpellier, France, September 1991
美法联合研讨会:多重 Sigma 和 PCP 受体配体:神经调节和保护机制,法国蒙彼利埃,1991 年 9 月
- 批准号:
9015992 - 财政年份:1991
- 资助金额:
$ 7.15万 - 项目类别:
Standard Grant
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2118616 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别:
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2331142 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别:
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2118615 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别:
PCP RECEPTOR CHARACTERIZATION WITH NEW AFFINITY LIGANDS
用新亲和配体表征 PCP 受体
- 批准号:
3213399 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别:
PCP RECEPTOR CHARACTERIZATION WITH NEW AFFINITY LIGANDS
用新亲和配体表征 PCP 受体
- 批准号:
3213401 - 财政年份:1990
- 资助金额:
$ 7.15万 - 项目类别: